Intech Investment Management LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 21.6% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 105,960 shares of the biopharmaceutical company’s stock after selling 29,273 shares during the quarter. Intech Investment Management LLC’s holdings in Gilead Sciences were worth $15,793,000 at the end of the most recent reporting period.
A number of other large investors also recently added to or reduced their stakes in GILD. Silver Oak Securities Incorporated lifted its stake in Gilead Sciences by 4.1% in the 3rd quarter. Silver Oak Securities Incorporated now owns 3,790 shares of the biopharmaceutical company’s stock valued at $565,000 after buying an additional 149 shares in the last quarter. Heritage Trust Co boosted its holdings in Gilead Sciences by 3.7% in the 3rd quarter. Heritage Trust Co now owns 45,736 shares of the biopharmaceutical company’s stock worth $6,817,000 after buying an additional 1,623 shares during the last quarter. Wall Street Financial Group Inc. boosted its holdings in Gilead Sciences by 4.3% in the 3rd quarter. Wall Street Financial Group Inc. now owns 2,662 shares of the biopharmaceutical company’s stock worth $397,000 after buying an additional 110 shares during the last quarter. White Pine Capital LLC acquired a new stake in Gilead Sciences in the 3rd quarter worth about $455,000. Finally, Bessemer Group Inc. increased its stake in Gilead Sciences by 17.7% during the 3rd quarter. Bessemer Group Inc. now owns 1,699,016 shares of the biopharmaceutical company’s stock worth $253,238,000 after buying an additional 254,994 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of brokerages have commented on GILD. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Bank of America raised their target price on Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a research note on Tuesday, October 20th. Wells Fargo & Company lifted their price target on Gilead Sciences from $165.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. TD Cowen boosted their price target on shares of Gilead Sciences from $160.00 to $175.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Finally, Argus set a $190.00 price objective on shares of Gilead Sciences in a report on Thursday. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $171.63.
Read Our Latest Stock Report on Gilead Sciences
Insider Transactions at Gilead Sciences
In related news, CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the transaction, the chief financial officer owned 161,096 shares of the company’s stock, valued at approximately $25,166,417.12. This represents a 1.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 9,810 shares of the firm’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $175.17, for a total value of $1,718,417.70. Following the transaction, the chief executive officer owned 551,683 shares of the company’s stock, valued at $96,638,311.11. This trade represents a 1.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 211,709 shares of company stock worth $35,234,427 over the last quarter. 0.30% of the stock is owned by corporate insiders.
Gilead Sciences Stock Down 0.3%
Gilead Sciences stock opened at $167.58 on Tuesday. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $176.58. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.22 and a current ratio of 1.38. The firm has a 50 day moving average price of $155.43 and a 200 day moving average price of $141.94. The company has a market capitalization of $207.86 billion, a PE ratio of -53.03 and a beta of 0.35.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The company had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. During the same period in the prior year, the firm earned $2.47 earnings per share. The firm’s revenue was up 6.8% compared to the same quarter last year. Research analysts expect that Gilead Sciences, Inc. will post -0.97 earnings per share for the current year.
Gilead Sciences Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.0%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s payout ratio is currently -103.80%.
Key Stories Impacting Gilead Sciences
Investors following GILD have been watching these stories:
- Positive Sentiment: Gilead signed royalty-free voluntary licensing agreements with three generic manufacturers to support potential future access to investigational obeldesivir for Ebola Bundibugyo virus disease post-exposure prevention in 127 primarily low- and lower-middle-income countries. This may broaden access and strengthen Gilead’s profile, though the drug is not yet approved. Reuters article
- Neutral Sentiment: Barclays raised its price target from $145 to $160 but kept an “equal weight” rating. The higher target is an improvement, although it remains below the stock’s cited recent price, signaling a measured view of further upside. Barclays ratings
- Negative Sentiment: Zacks Research made mixed earnings revisions: it lowered its Q4 2026 EPS estimate to $1.31 from $2.14 and its FY2026 estimate to a loss of $0.86 per share from a loss of $0.65, while slightly raising its Q1 2028 forecast. The near-term cuts may weigh on sentiment. Zacks Research forecast article
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
Recommended Stories
- Five stocks we like better than Gilead Sciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
